← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Non-nucleoside reverse transcriptase inhibitors
elsulfavirine
J05AG07
Adult Dosing
- 20 mg orally once daily in combination with other antiretroviral agents
Pediatric Dosing
- Safety and efficacy in pediatric patients under 18 years of age not established
Indications
- Treatment of HIV-1 infection in treatment-naive adults as part of a combination antiretroviral regimen
Mechanism of Action
- Non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1, binding directly to reverse transcriptase and blocking RNA- and DNA-dependent DNA polymerase activities
Contraindications
- Hypersensitivity to elsulfavirine or any component of the formulation
- Co-administration with strong CYP3A4 inducers or inhibitors due to significant alteration of plasma concentrations
Adverse Reactions
- Headache
- Dizziness
- Nausea
- Diarrhea
- Insomnia
- Elevated transaminases
- Rash
Drug Interactions
- Contraindicated with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort) which significantly decrease elsulfavirine concentrations
- Use with caution alongside medications metabolized by CYP enzymes or transported by P-glycoprotein
Curated Content: Needs Vetting Before Put to Clinical Use